Objective measurement of cough in pulmonary fibrosis: a cohort study - ImpaCT

Jad Kebbe; Simon P Hart; Robert J Kaner; Tejaswini Kulkarni; Lutz Wollin; Carl Coeck; Richard Vinisko; Nina Patel; Marlies S Wijsenbeek

doi:10.1183/23120541.00310-2024

Objective measurement of cough in pulmonary fibrosis: a cohort study - ImpaCT

ERJ Open Res. 2024 Sep 30;10(5):00310-2024. doi: 10.1183/23120541.00310-2024. eCollection 2024 Sep.

Authors

Jad Kebbe¹, Simon P Hart², Robert J Kaner³, Tejaswini Kulkarni⁴, Lutz Wollin⁵, Carl Coeck⁶, Richard Vinisko⁷, Nina Patel⁷, Marlies S Wijsenbeek⁸

Affiliations

¹ Section of Pulmonary, Critical Care and Sleep Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
² Hull York Medical School, University of Hull, Hull, UK.
³ Division of Pulmonary and Critical Care Medicine and Department of Genetic Medicine, Weill Cornell Medicine, New York, NY, USA.
⁴ University of Alabama at Birmingham, Birmingham, AL, USA.
⁵ Boehringer Ingelheim Pharma GmbH & Co, KG, Biberach an der Riß, Germany.
⁶ Boehringer Ingelheim SComm, Brussels, Belgium.
⁷ Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
⁸ Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

Abstract

Using both objective cough monitoring and patient-reported outcomes measures, this study describes the burden of cough for patients with non-IPF pulmonary fibrosis https://bit.ly/3wFm0th.